

DEVELOPMENT OF CATHEPSIN K INHIBITORS FOR THE TREATMENT OF BONE DISORDERS

Cheuk K. Lau^a, Christophe Mellon^a, and Elise Isabel^a, Sylvie Desmarais^b, Jean-Pierre Falgueyret^b, Frederic Massé^b, M. David Percival^b, Gregg Wesolowski^c

^aDepartment of Medicinal Chemistry, ^bDepartment of Biochemistry, Merck Frosst Centre for Therapeutic Research, Kirkland, Quebec, Canada. ^cDepartment of Molecular Endocrinology, Merck Research Laboratories, West Point, PA, USA.

A series of potent diarylmethylether cathepsin K inhibitors was developed. Replacement of the P2-P3 amide bond of dipeptide based nitrile inhibitors with a diarylmethylether gave potent and selective cathepsin K inhibitors.

